Telix Pharmaceuticals Ltd. ( (AU:TLX) ) has provided an update.
Telix Pharmaceuticals Limited announced the release of 717,587 ordinary shares from voluntary escrow, which were initially issued as part of the acquisition of IsoTherapeutics Group, LLC. This release, scheduled for 9 April 2025, reflects a strategic move following the acquisition, potentially impacting the company’s market dynamics and stakeholder interests.
More about Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing diagnostic and therapeutic radiopharmaceuticals and associated medical devices. Headquartered in Melbourne, Australia, Telix operates internationally in the United States, Europe, and Japan. The company aims to address significant unmet medical needs in oncology and rare diseases, with its lead imaging product, Illuccix®, approved by regulatory bodies in the U.S., Australia, and Canada.
YTD Price Performance: 20.80%
Average Trading Volume: 5,339
Technical Sentiment Signal: Sell
Current Market Cap: $5.59B
See more insights into TLX stock on TipRanks’ Stock Analysis page.